𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imaging biomarkers as surrogate endpoints for drug development

✍ Scribed by Wolf S. Richter

Publisher
Springer
Year
2006
Tongue
English
Weight
100 KB
Volume
33
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Modulation of DNA hypomethylation as a s
Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer
✍ Lianhui Tao; Wei Wang; Paula M. Kramer; Ronald A. Lubet; Vernon E. Steele; Micha πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 171 KB

## Abstract Surrogate end‐point biomarkers are being developed as indicators of the efficacy of chemopreventive agents. These biomarkers are molecular and biological end‐points that can be modulated by chemopreventive agents in accordance with their efficacy to prevent cancer. DNA hypomethylation i

Subjects and recruitment strategies for
Subjects and recruitment strategies for a short-term phase II chemoprevention trial of breast cancer using surrogate endpoint biomarkers
✍ Victor G. Vogel πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 177 KB

Progression of breast neoplasia is characterized by a variety of causal and nonspecific molecular, karyotypic, and cellular level genetic alterations. These include allelic losses, chromosomal rearrangements, and aneusomies, as well as widely divergent clonal DNA content aberrations. Establishment o